Business
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor
Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra® (resmetirom) for potential additive therapeutic benefit in MASHMadrigal to present at the 44th Annual J.P. Morgan Healthcare Conference at 1:30 p.m. PST (4:30 p.m. EST) on Monday, January 12, 2026 CONSHOHOCKEN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical compa
About this update from Pfizer, Inc.
[{"type":"image","alt":"Madrigal Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Madrigal Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/0a35449b0ee323b8224d49bf845d4cf5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8bWqK589xSpgJhdPdvdrmw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0a35449b0ee323b8224d49bf845d4cf5","width":300,"height":86}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapies","length":97,"tagName":"p"}]},{"val":[{"type":"text","content":"DGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra® (resmetirom) for potential additive therapeutic benefit in MASH","length":144,"tagName":"p"}]},{"val":[{"type":"text","content":"Madrigal to present at the 44th Annual J.P. Morgan Healthcare Conference at 1:30 p.m. PST (4:30 p.m. EST) on Monday, January 12, 2026","length":133,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":374,"olType":false},{"type":"text","content":"CONSHOHOCKEN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced an exclusive global license agreement with Pfizer for ervogastat, a clinical-stage oral DGAT-2 inhibitor, strengthening the company’s leadership in shaping the next generation of MASH therapies and combination regimens. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage, resulting in lower hepatic triglycerides, reduced lipotoxic fat and decreased inflammation in the liver.","length":658,"tagName":"p"},{"type":"text","content":"The company will present more details at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 1:30 p.m. PST. The presentation will be webcast live and can be accessed here or by visiting Madrigal’s Investor Relations site, Events and Presentations page.","length":281,"tagName":"p"},{"type":"text","content":"“Madrigal is committed to building the industry-leading pipeline that will shape the future of MASH care and ...